Nuvalent, Inc. (NUVL) Stock

Nuvalent, Inc. (NUVL) is a Healthcare stock trading at $123.41 (as of 2026-06-18), with a market capitalization of $8.68B and a trailing P/E of -18.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies. Its pipeline includes NVL-520, an inhibitor targeting ROS1 fusions, and NVL-655, an inhibitor targeting ALK, each designed for activity in central nervous system disease contexts and currently in Phase I or Phase I/II clinical development.

Valuation — source: SEC EDGAR (first-party)

Price	$123.41
Market Cap	$8.68B
P/E Ratio	-18.2
Price / Book	7.39
DCF Value (model)	$-60.86
DCF Upside vs Price	-149.3%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$44.79M
Net Margin	-949.6%
Return on Equity	-38.3%
Current Ratio	16.14
Revenue Growth (YoY)	16.7%
EPS Growth (YoY)	48.9%

Financial Health — source: SEC EDGAR

Altman Z-Score

31.95 (safe)

Valuation vs Sector & Industry

Stock P/E	-18.2
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-186.9%
vs Industry	-205.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	DEERFIELD MANAGEMENT COMPANY, L.P. ($1.77B)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	James R. Porter
Employees	162
Country	US
IPO Date	2021-07-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Halozyme Therapeutics, Inc. (HALO)
• Cytokinetics, Incorporated (CYTK)
• Praxis Precision Medicines, Inc. (PRAX)
• Krystal Biotech, Inc. (KRYS)
• Rhythm Pharmaceuticals, Inc. (RYTM)
• Kymera Therapeutics, Inc. (KYMR)
• PTC Therapeutics, Inc. (PTCT)
• Vaxcyte, Inc. (PCVX)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.